April 11, 2023 02:46 PM EDT

Four years later, FDA finalizes guidance on risk-based monitoring of clinical trials

Zachary Brennan

Senior Editor

How much or how little oversight is necessary for a clinical trial to succeed? That’s the billion-dollar question the FDA hopes to help industry better …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Four years later, FDA finalizes guidance on risk-based monitoring of clinical trials

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Exclusive: Florida cancer biotech raises $100M Series A

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Four years lat­er, FDA fi­nal­izes guid­ance on risk-based mon­i­tor­ing of clin­i­cal tri­als

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Four years later, FDA finalizes guidance on risk-based monitoring of clinical trials

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Exclusive: Florida cancer biotech raises $100M Series A

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings